Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Exp Immunol ; 157(2): 291-9, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19604269

ABSTRACT

Tumour necrosis factor (TNF)-alpha is crucial for resistance to Trypanosoma cruzi acute infection, but there is scant information on its role during the chronic phase. To address this issue, we analysed whether a short treatment with a TNF-alpha blocker affected the course and characteristics of chronic disease in a rat experimental model of T. cruzi infection. An anti-TNF-alpha agent (infliximab) was administered during the chronic phase for a period of 4 weeks (3 mg/kg/week), while control infected rats were inoculated with saline physiological solution. Search for parasites yielded non-successful results in all infected groups, irrespective of treatment. Nevertheless, the presence of T. cruzi kDNA in heart tissue was detected in infected and infected plus treated animals. Because infliximab might induce changes in the anti-parasite cytokine response, circulating levels of interleukin (IL)-10, interferon-gamma and nitric oxide were evaluated. An increase in IL-10 levels was observed only in the infected group treated with the anti-TNF-alpha blocker compared to the remaining groups (P < 0.05). A clear attenuation of histological damage associated with a diminution of cardiac TNF-alpha mRNA expression was observed in the infected and treated animals compared to the infected and non-treated group. Blocking of TNF-alpha during a relatively short period in chronically infected rats did not lead to evident parasite reactivation but reduced myocarditis severity significantly, indicating a role of this cytokine in the pathogenesis of chronic myocardial damage.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Chagas Cardiomyopathy/drug therapy , Immunosuppressive Agents/therapeutic use , Trypanosoma cruzi , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Animals , Antibodies, Monoclonal/pharmacology , Antibodies, Protozoan/immunology , DNA, Protozoan/analysis , Heart/parasitology , Immunohistochemistry , Immunosuppressive Agents/pharmacology , Infliximab , Male , Models, Animal , Parasitemia/diagnosis , RNA, Messenger/analysis , Random Allocation , Rats , Reverse Transcriptase Polymerase Chain Reaction/methods , Trypanosoma cruzi/genetics , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/immunology
2.
Vaccine ; 25(17): 3492-500, 2007 Apr 30.
Article in English | MEDLINE | ID: mdl-17368877

ABSTRACT

The well-established model of Chagas' disease in "l" rats was used to evaluate the effects of three injections of heat-killed Gordonia bronchialis, Rhodococcus coprophilus or saline on Trypanosoma cruzi parasitaemia and acute and chronic myocarditis, sequelae of the infection. Two vaccinating injections were given prior to challenge with T. cruzi, and the third, immunotherapeutic, injection was given 7 days after challenge. Treatment with either actinomycete significantly reduced acute parasitaemia (p<0.04), modified cellular infiltration during acute myocarditis and limited chronic myocarditis (p<0.03) in comparison with the saline-treated control animals. Immunological investigations showed that both bacterial preparations achieved their results through different mechanisms. The relevance of our findings to human Chagas' disease is discussed.


Subject(s)
Actinomycetales/immunology , Chagas Disease/immunology , Immunization , Animals , Antibodies, Protozoan/blood , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Chagas Cardiomyopathy/immunology , Environmental Microbiology , Immunoglobulin G/blood , Male , Parasitemia/prevention & control , Rats , Suspensions
SELECTION OF CITATIONS
SEARCH DETAIL
...